Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Operating Margin (2016 - 2025)

Historic Operating Margin for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 83.06%.

  • China Pharma Holdings' Operating Margin rose 155800.0% to 83.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.83%, marking a year-over-year increase of 27200.0%. This contributed to the annual value of 101.32% for FY2024, which is 620800.0% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Operating Margin is 83.06%, which was up 155800.0% from 63.57% recorded in Q2 2025.
  • China Pharma Holdings' Operating Margin's 5-year high stood at 20.28% during Q1 2023, with a 5-year trough of 150.44% in Q2 2024.
  • Moreover, its 5-year median value for Operating Margin was 48.33% (2022), whereas its average is 57.54%.
  • As far as peak fluctuations go, China Pharma Holdings' Operating Margin plummeted by -1088800bps in 2024, and later soared by 868700bps in 2025.
  • Over the past 5 years, China Pharma Holdings' Operating Margin (Quarter) stood at 22.45% in 2021, then tumbled by -78bps to 40.02% in 2022, then plummeted by -38bps to 55.1% in 2023, then tumbled by -91bps to 105.47% in 2024, then increased by 21bps to 83.06% in 2025.
  • Its Operating Margin stands at 83.06% for Q3 2025, versus 63.57% for Q2 2025 and 66.76% for Q1 2025.